Executive Summary
PARTNER 3's 7-year readout, presented via ACC, is the day's story — the first pivotal low-risk TAVR trial to cross the 7-year mark, arriving on the same day CMS opened a new National Coverage Analysis on TAVR reimbursement. A separate meta-analysis of 11,572 patients with prior chest radiation found no mortality difference between TAVR and SAVR but a doubling of pacemaker risk and quadrupling of moderate-plus AR with TAVR — a reminder that the low-risk case is still built on trade-offs, not superiority. Together these datapoints tighten the case that durability, not 30-day event rates, will decide where the SAVR-TAVR line sits when the next guideline cycle opens.
- A 7-year Turkish single-center cohort of early-generation SAPIEN XT reported Stage 2-3 SVD of 3.72% and BVF 2.23%, but only 29.6% cumulative survival — competing mortality obscures the durability signal (Anatolian J Cardiol).
- A meta-analysis in TAVR/TEER patients with AF found oral anticoagulation associated with lower bleeding and mortality vs antiplatelet therapy, but the evidence base is four observational cohorts totaling 2,098 patients (Front Cardiovasc Med).
- Deep-learning biological age from preoperative chest radiographs outperformed EuroSCORE II for 30-day mortality in TAVI (AUC 0.952 vs 0.745, P=0.004) in a 1,269-patient single-center dataset (EHJ Digital Health).
- P&F Products acquired Austrian mitral device startup AVVie, extending private-market consolidation in structural heart (Morningstar).
- Boston Scientific fell 2.75% to $47.74, extending a 6-month drawdown of 37.41% and diverging sharply from Edwards' 13% gain over the same window (Yahoo Finance).
What to watch: The CMS proposed decision memo on TAVR coverage (CAG-00430N) sets the near-term reimbursement direction — the next comment cycle and finalization will determine whether the 7-year PARTNER 3 data translates into policy change.
Aortic Valve (TAVR/TAVI)
The 7-year PARTNER 3 data, reported through ACC's coverage, is [NOTABLE]: the first pivotal low-risk TAVR trial to reach this horizon in a population young enough that durability is the question that matters. NEJM published the primary trial in 2019, and the 5-year data already softened the early narrative of TAVR superiority. Long-term follow-up in patients who were, on average, in their mid-70s at randomization still sidesteps the core issue: what happens in patients <70 with 15-20 year life expectancy? The ESC 2025 guidelines resolved that question by moving the TAVR-preferred threshold to ≥70 years (Class I), and by setting <70 as a SAVR zone when surgical risk is low. The ACC/AHA 2020 framework, with its <65/65-80/>80 tiers, remains in effect until a US update incorporates this data — a gap CMS's new NCA (CAG-00430R, with a proposed decision memo CAG-00430N) may partially fill.
Supporting data today: a meta-analysis of 11,572 chest-radiation patients found no 30-day or 1-year mortality difference between TAVR and SAVR, with TAVR advantages in bleeding (OR 0.38), AKI (OR 0.51), and post-op AF (OR 0.20), but a 2.27-fold higher pacemaker rate and 4.44-fold higher moderate-plus AR — the durability-relevant complications. A 7-year Turkish SAPIEN XT registry (n=270) reported low Stage 2-3 SVD (3.72%) but 29.6% survival, illustrating why competing mortality still masks the durability signal in older cohorts.
Mitral Valve (MitraClip, PASCAL, TMVR)
A network meta-analysis of antithrombotic strategies after TMVR/TEER in AF patients (four observational cohorts, n=2,098) favored oral anticoagulation over antiplatelet therapy for bleeding, mortality, and stroke — but the evidence base is exactly what the authors call it: heterogeneous, non-randomized, and dominated by one or two studies per contrast. Neither ACC/AHA 2020 nor ESC 2025 offer a firm recommendation on post-TEER antithrombotic therapy in AF, and this analysis doesn't change that. It reinforces clinical practice (most operators default to OAC when AF is present) without providing the RCT-grade evidence needed for a guideline upgrade.
A porcine preclinical study of the L-Clip direct transcatheter mitral annuloplasty device reported 100% procedural success in 18 animals with 26% annular area reduction and no serious adverse events. Preclinical only, industry-relevant given surgical annuloplasty's durability advantage — the field's unmet need remains a transcatheter annuloplasty option that reproduces surgical results in secondary MR. A case report of dynamic ischemic MR treated with M-TEER after failed revascularization illustrates the diagnostic gap for exercise-provoked MR that resting studies miss. ESC 2025 has TEER as Class I for ventricular SMR meeting COAPT criteria; ACC/AHA 2020 remains Class IIa.
Tricuspid Valve (TriClip, TTVR)
A JACC Case Reports description of transjugular T-TEER for hostile IVC anatomy addresses a real gap — the transfemoral-first design of every commercial T-TEER system excludes a small but relevant subset with occluded IVC, hostile venous anatomy, or prior IVC filter complications. Single case, but technically important given ESC 2025 elevated transcatheter TV treatment to Class IIa for symptomatic high-risk severe TR based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 predates all three trials and has no recommendation on transcatheter TR therapy — the US-Europe divergence here is the widest of any valve indication. Real-world STS/ACC TVT Registry data on the EVOQUE system continues to build the case for TTVR, but the surgical comparator remains poorly defined; concomitant TV surgery during left-sided operations is Class I in both guidelines, but isolated TV surgery mortality historically ran 8-20%, which is why the transcatheter option exists in the first place.
Surgical vs. Transcatheter Comparisons
The radiation-history meta-analysis is the day's most direct SAVR-vs-TAVR comparison and it favors TAVR for peri-procedural morbidity — as expected in a population where prior thoracic radiation makes redo sternotomy technically difficult. This is one of the cleanest indications where both ACC/AHA 2020 and ESC 2025 explicitly list "prior chest radiation" as favoring TAVR. What the meta-analysis doesn't resolve: the 4.44-fold higher moderate-plus AR and 2.27-fold higher pacemaker rate matter more at 10 years than at 30 days, and this cohort skews older with limited long-term data. The 7-year PARTNER 3 update is the more consequential SAVR-vs-TAVR readout today, but the population (low-risk, mean age ~74) doesn't answer the question the field actually needs answered: how do these valves perform in patients under 70?
Preprint Highlights
Today's biorxiv preprint on small intestinal Lactobacillaceae is outside the valve space and not relevant to structural heart practice.
Device & Technology
Two AI/imaging validation studies landed. The Mimics for TAVR AI planning platform (Materialise) achieved ICCs of 0.90-0.98 vs semi-automated software across annular area, LVOT, sinotubular junction, and coronary heights in 126 patients, cutting analysis time from 9.55 to 1.03 minutes. Vendor-driven validation, but the workflow gains matter — pre-TAVR planning bottlenecks are real. Separately, deep-learning biological age from chest radiographs outperformed EuroSCORE II for 30-day mortality (AUC 0.952 vs 0.745 in TAVI; P=0.004) in 1,269 patients at a single center. Patients whose biological age exceeded chronological by >10 years had 17.3% vs 9.2% major complication rates. Single-center, retrospective — but the direction (imaging-derived biological age adds prognostic value beyond risk scores) is consistent with the frailty literature. An explainable ML model for TAVI outcome prediction (n=256, single Qatar center) is more preliminary — small sample, SMOTE-generated synthetic data, no external validation.
Regulatory & Policy
CMS opened National Coverage Analysis CAG-00430R on TAVR and released a proposed decision memo CAG-00430N. This is the most consequential US TAVR policy action since the 2019 low-risk expansion. Watch for center volume requirements, heart team composition, and shared decision-making mandates — these are the mechanisms through which CMS shapes practice patterns without directly setting age thresholds. The timing, on the same day as 7-year PARTNER 3 data, is unlikely to be coincidental.
Industry & Market
P&F Products & Features GmbH acquired AVVie GmbH, an Austrian mitral device startup. Terms undisclosed. Private-market activity in mitral remains steady, driven by the size of the TEER-ineligible SMR population and the durability gap between surgical and transcatheter annuloplasty.
Financial Analysis
The single most important financial story remains Boston Scientific's continued underperformance — down 37.41% over 6 months, closing at $47.74 today after a 2.75% drop. The company's structural heart franchise (WATCHMAN, ACURATE neo2, Sentinel) has been under pressure, and the 6-month divergence from Edwards (+13.04%) is the clearest signal that the market is separating pure-play structural heart exposure from diversified med-tech. Analyst target of $62.69 implies 31% upside, but the sell-side has been slow to reset in the sector. Medtronic (-14.99% over 6 months) similarly reflects diversified med-tech pressure. Edwards' outperformance is the tell: with PARTNER 3 7-year data landing and CMS opening the TAVR NCA, the market is pricing in continued dominance in low-risk TAVR, offset by the reality that Edwards' TAVR growth is now maturity-limited in developed markets. Anteris Technologies (AVR.AX) is up 48.38% over 6 months on the DurAVR clinical program — a reminder that clinical-stage TAVR platforms can still command growth premiums when SAVR-vs-TAVR conversations reopen.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $88.97, -0.70% on the day; 6-month +13.04%
- Market cap $51.3B; P/E trailing 53.28, forward 26.36; beta 0.85
- 52-week range $72.30-$96.29
- Analyst target $100.96 (26 analysts, buy consensus)
- Next earnings 2026-10-29 (EPS est $0.74, Rev est $1.68B)
- Commentary: 7-year PARTNER 3 data and the CMS NCA are the near-term catalysts. Edwards' TAVR moat remains, but growth is maturity-limited in developed markets.
Medtronic (MDT)
- Close $85.99, -0.24% on the day; 6-month -14.99%
- Market cap $110.1B; P/E trailing 23.12, forward 13.41; beta 0.57
- 52-week range $73.31-$106.33
- Analyst target $98.44 (25 analysts, buy consensus)
- Next earnings 2026-09-01 (EPS est $1.39, Rev est $9.55B)
- Commentary: Structural heart (Evolut) growth is intact but diluted within a diversified portfolio under pressure.
Abbott (ABT)
- Close $105.71, +0.24% on the day; 6-month -3.34%
- Market cap $184.1B; P/E trailing 34.21, forward 17.44; beta 0.58
- 52-week range $81.97-$137.49
- Analyst target $118.42 (24 analysts, buy consensus)
- Next earnings 2026-10-14 (EPS est $1.42, Rev est $12.99B)
- Commentary: MitraClip and TriClip franchises remain the structural heart differentiators; ESC 2025 Class I upgrade for TEER in ventricular SMR supports the mitral thesis.
Boston Scientific (BSX)
- Close $47.74, -2.75% on the day; 6-month -37.41%
- Market cap $69.2B; P/E trailing 19.33, forward 13.88; beta 0.57
- 52-week range $42.20-$109.50
- Analyst target $62.69 (29 analysts, buy consensus)
- Next earnings 2026-10-21 (EPS est $0.81, Rev est $5.26B)
- Commentary: The Yahoo Finance question ("buy despite risks?") captures the setup — sell-side targets still imply 31% upside but the sector has repriced ACURATE and WATCHMAN growth expectations sharply lower.
Anteris Technologies (AVR.AX)
- Close A$10.98, -4.44% on the day; 6-month +48.38%
- Market cap A$1.1B; forward P/E -5.04; beta 0.73
- 52-week range A$5.20-A$15.47
- Analyst target A$13.00 (1 analyst)
- Commentary: Clinical-stage DurAVR platform benefiting from renewed SAVR-vs-TAVR debate and the durability question that PARTNER 3 has not yet answered for younger patients.
Market outlook: The Edwards-Boston Scientific divergence is the single cleanest signal in the sector — pure-play TAVR leadership is being rewarded, structural heart diversification is not. Watch how the CMS NCA finalizes and whether the ESC 2025 age threshold shift bleeds into US practice ahead of the next ACC/AHA update.
Clinical Trial Updates
Mitral Repair
- NCT04729933 — Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Following MitraClip. Status: Active, not recruiting. Enrollment 16. Sponsor: Samir Kapadia (Cleveland Clinic). Small proof-of-concept study addressing residual LA pressure elevation post-TEER — a mechanistic question relevant to the atrial SMR phenotype newly defined in ESC 2025.
Landmark trials to watch as PARTNER 3 crosses 7 years: EARLY TAVR (asymptomatic AS), TRILUMINATE Pivotal (T-TEER), TRISCEND II (TTVR), REPAIR-MR (PMR), and COAPT/RESHAPE-HF2 (ventricular SMR) — the pipeline that will define the next ACC/AHA guideline cycle.
Social & Conference Highlights
The PARTNER 3 7-year presentation will drive the next 48 hours of structural heart discussion, particularly as it lands alongside the CMS NCA. Watch for surgical commentary from Badhwar, Mehaffey, and Chikwe on the durability signal in the low-risk cohort as more data becomes available.
Next: The 7-year PARTNER 3 manuscript publication in a major journal (NEJM or JACC likely) and CMS's response window on CAG-00430N will together set the direction for US TAVR policy through 2027. The ESC 2025 age threshold shift and the ACC/AHA 2020 framework remain in tension until the next US guideline cycle opens.